Skip to content

BioLife Solutions BLFS Available for sale investments

Available for sale investments at other companies

Azenta logo
AzentaAZTA
Baxter International logo
Baxter InternationalBAX
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.34B+33.1%
Enterprise value$1.34B+38.1%
P/S13.5×+0.6×

Profitability

See full
Gross margin66.9%
Operating margin-16.7%
Net margin-68.7%
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's available for sale investments?
BioLife Solutions (BLFS) reported available for sale investments of $88.67M in Q1 2026.
How has BioLife Solutions's available for sale investments changed year-over-year?
BioLife Solutions's available for sale investments increased by 117.9% year-over-year, from $40.69M to $88.67M.
What is the long-term trend for BioLife Solutions's available for sale investments?
Over 3 years (2022 to 2025), BioLife Solutions's available for sale investments has grown at a 25.0% compound annual growth rate (CAGR), from $44.59M to $87.14M.